Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.

Citi analyst Geoff Meacham lowered the firm’s price target on Eli Lilly to $1,190 from $1,250 and keeps a Buy rating on the shares. Ahead of ...

Wells Fargo lowered the firm’s price target on Eli Lilly (LLY) to $970 from $1,000 and keeps an Overweight rating on the shares. The firm ...

US Dollar South African Rand, Coca-Cola Co, Eli Lilly and Company, Apple Inc. Read Vestact 's latest article on Investing.com South Africa.

FFO, a key performance measure for REITs, came in at $411.8 million, or $2.39 per share, for the quarter, compared with $389.8 million, or $2.28 per share, a year ago. Its total revenue for the ...

Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...

The Nasdaq Composite slid more than 3% in Monday’s trading as a slate of AI-related plays, including chip darling Nvidia, ...

Eli Lilly and Company ( NYSE:LLY – Get Free Report) last issued its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

Allurion catapulted nearly 200% early Friday after the company said it plans to test its weight-loss technology with an ...

When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...